Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYLVER: first-in-human study of GSK4418959 in dMMR/MSI-H solid tumors
2024-519721-37-00Phase 2Authorised
- Sponsor
- GSK
- Start
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of GSK4418959 and dostarlimab in Nonhematologic neoplasms, colorectal cancer (CRC) and endometrial cancer (EC) (3 arms), sponsored by GSK. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events during DLT period and 2 more. Planned start Jul 2025; status: authorised.
02
Drugs
GSK4418959dostarlimab
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)endometrial cancer (EC)
Beyond the preview
Go deeper on 2024-519721-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519721-37-00.